NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization312.43 mln
Float20.14 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-5.47
Highly reliable
1-Year Forecast
40.09
Transformational upside
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-73.16
Deeply negative
Business Description
Founded in 2011 and based in Rockville, Maryland, Avalo Therapeutics is a U.S. biotech company working to bring new treatments to patients whose immune systems cause harmful inflammation. The company's most advanced drug candidate, AVTX-009, is currently being tested in a mid-stage clinical trial targeting a protein linked to inflammatory conditions. Previously operating under the name Cerecor Inc., the company rebranded as Avalo Therapeutics in August 2021.
